Joint Ventures Recaps Influential EULAR Studies in SLE, RA, and More ByRihards Buss, MD,Jack Arnold, MBBS, MRCP, PhDJuly 16th 2026
Belimumab Nearly Doubled Non-GC Remission and LLDAS Rates in SLE Post-HocsByVictoria JohnsonJuly 14th 2026
What We're Looking Forward to in Rheumatology in H2 2026ByRheumatologyLive Editorial StaffJuly 8th 2026
Enpatoran Gets FDA Breakthrough Therapy Designation for Lupus With Cutaneous ManifestationsByVictoria JohnsonJuly 8th 2026